Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPX-201 + AP1903
- Development stage
- Discontinued
- Lead developer
- Bellicum Pharmaceuticals
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intravenous
01
Overview
BPX-201 + AP1903 is a combination immunotherapy developed by Bellicum Pharmaceuticals for the treatment of metastatic castration-resistant prostate cancer (mCRPC). BPX-201 is an autologous dendritic cell vaccine engineered with the proprietary DeCIDe "on switch" and trained to target prostate cancer cells, specifically those expressing prostate-specific membrane antigen (PSMA). The dendritic cells are transduced with an adenoviral vector encoding inducible MyD88/CD40 signaling elements, enhancing their ability to stimulate cytotoxic T lymphocytes. After administration of the vaccine, patients receive AP1903 (also known as rimiducid), a small molecule dimerizer that activates the engineered signaling pathway in vivo. This activation is designed to occur after dendritic cells have migrated to lymph nodes, aiming for a more potent and durable antigen-specific T cell immune response. The combination was evaluated in phase I clinical trials but development was discontinued following company wind-down[1][2][5][7].
- Other names
- Second generation autologous DeCIDe vaccine (BPX-201)Rimiducid (for AP1903)
02
Targets
CD40 (Cluster of differentiation 40 receptor)
Beyond the preview
Go deeper on BPX-201 + AP1903.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BPX-201 + AP1903.